GW Pharmaceuticals plc (GWPH) continues to deliver...
Today, GW along with its subsidiary Greenwich Biosciences, completed the rolling submission of a New Drug Application (NDA) to the FDA for Epidiolex as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome, two highly treatment-resistant forms of childhood-onset epilepsy.
Although the Nasdaq traded at a new all-time high and was the top performing exchange yesterday, biotech stocks moved lower as the iShares Nasdaq Biotechnology ETF (IBB) fell less than 1%.
Despite the post-election rally, the biotech sector has been under pressure due to President Trump’s comments pertaining to lowering drug prices. Although we expect to see several biotech companies negatively impacted by future changes in pricing, many companies will not be affected.
Cannabis stocks ended the year on a high note and 2016 was a great year for the cannabis industry. From Canada to Australia, the United States to Germany, the global cannabis industry continued to expand and the stage is set for further growth in 2017.
Although the cannabis sector saw a turnaround in 2016, the sector really started to rally in late August and we want to highlight 11 cannabis stocks that investors should watch during 2017.
Today marks the final trading day of 2016 and this year will certainly be one that cannabis investors remember forever.
As we approach the new year, market sentiment remains in positive territory as companies are better positioned for success than ever before.
From the rise of the Canadian cannabis industry to election of Donald Trump, there will be a lot for investors to watch during 2017 and we want to highlight some themes we expect to play out over the course of the year
Agencies across the globe continue to recognize the medical benefits associated with cannabis. It is only a matter of time before this incredible plant will be legalized in the United States.
The cannabis sector has been under heavy pressure during the last week and this weakness has been the result of several factors.
From an overextended industry wide rally to highly questionable cabinet nominations by president elect Donald Trump, concerns among cannabis investors have increased in the last week despite favorable election results.
Although cannabis stocks are still up significantly from their summer lows this last week has been very tough for the sector:
Although the biotech sector will be one of the greatest beneficiaries of the legal cannabis movement, the sector has recently been under pressure and this weakness has created significant opportunities for investors.